Bio Medica Laboratories IPO GMP Today, Price & Details
Bio Medica Laboratories IPO GMP Today, Price Band, Subscription Status, Allotment & Listing Details
About Bio Medica Laboratories
Bio Medica Laboratories is an SME poised to enter the public market via an IPO on the NSE, operating within the pharmaceutical and healthcare sector. The company's business appears focused on laboratory services, contributing to diagnostics and potentially research and development within the broader healthcare ecosystem. Its scale of operations, as indicated by its financial figures, suggests a niche but potentially growing presence. The IPO aims to raise capital for expansion and other corporate purposes.
Financially, Bio Medica Laboratories presents an interesting profile. For the period under review, it reported revenues of ₹28.55 Cr and a Profit After Tax (PAT) of ₹8.66 Cr. This translates to a robust Earnings Per Share (EPS) of ₹10.67. The IPO structure comprises a fresh issue of ₹47.19 Cr, which will directly fund the company's growth initiatives, alongside an Offer for Sale (OFS) component of ₹5.24 Cr, allowing existing shareholders to divest some of their holdings. The total issue size stands at ₹52.43 Cr.
The company's strong profitability margins and return ratios suggest a competitive edge within its operational segment. The use of proceeds from the fresh issue is expected to bolster its expansion plans, potentially enhancing its market position and operational capabilities. Investors will be keen to understand how this capital infusion will translate into future growth and sustained profitability, especially given the competitive landscape of the healthcare and diagnostics sector.
Bio Medica Laboratories IPO — Investment Analysis
The Bio Medica Laboratories IPO is priced at a band of ₹132 per share, with a face value of ₹10. Considering its EPS of ₹10.67, the Price-to-Earnings (P/E) ratio works out to approximately 12.38x. This valuation needs to be assessed against industry benchmarks and the company's growth prospects. A P/E of 12.38x is not excessively high, but its attractiveness hinges on the projected earnings growth and the company's ability to sustain its current profitability.
Financially, Bio Medica Laboratories exhibits strong performance indicators. Its revenue stood at ₹28.55 Cr, with a healthy PAT of ₹8.66 Cr, indicating robust profit margins. The EBITDA margin is particularly noteworthy at 39.83%. Return on Net Worth (RONW) is exceptionally high at 99.59%, and Return on Capital Employed (ROCE) is also strong at 48.2%. These ratios suggest efficient utilization of capital and strong profitability.
Looking ahead, the company's growth outlook appears positive, driven by the fresh capital infusion aimed at expansion. However, potential risks include the inherent volatility of the SME segment, which often carries higher risk than mainboard listings. The OFS component, while allowing liquidity for existing shareholders, doesn't directly contribute to the company's growth capital, which is a point to consider. Sector-specific regulatory changes and increased competition are also potential headwinds.
Subscription levels in the IPO will be a key indicator of market sentiment. Strong demand from Qualified Institutional Buyers (QIBs) and High Net-worth Individuals (HNIs) would signal confidence in the company's fundamentals and future prospects. Conversely, weak subscription, particularly from retail investors, might suggest caution. Investors should closely monitor these subscription figures as they can influence listing day performance and subsequent trading patterns. Investors should consult a SEBI-registered financial advisor before making investment decisions.
Disclaimer: This analysis is auto-generated from publicly available financial data and should not be considered investment advice. Always consult a SEBI-registered financial advisor before making investment decisions.
Bio Medica Laboratories IPO — Pros & Cons
Strengths
- The company boasts an impressive Return on Net Worth (RONW) of 99.59% and a strong Return on Capital Employed (ROCE) of 48.2%, indicating exceptional efficiency in utilizing shareholder funds and capital. This suggests a well-managed business that generates substantial returns on its investments, which is attractive for long-term value creation.
- Bio Medica Laboratories demonstrates very high profitability margins, with an EBITDA Margin of 39.83% and a PAT of ₹8.66 Cr on revenues of ₹28.55 Cr. These strong margins suggest pricing power and efficient cost management, which can provide a buffer against market fluctuations and contribute to sustained profitability.
- The IPO features a significant fresh issue component of ₹47.19 Cr, which will directly bolster the company's capital base for expansion and growth initiatives. This infusion of funds is crucial for scaling operations, enhancing infrastructure, and potentially entering new markets, thereby driving future revenue and profit growth.
- The valuation, with a P/E ratio of approximately 12.38x based on the upper price band, appears reasonable when compared to its strong earnings potential and return ratios. This pricing offers a potential entry point for investors seeking exposure to a profitable company at a sensible valuation, especially considering its high profitability metrics.
- The company's Net Asset Value (NAV) stands at ₹16.05 per share, which is significantly lower than the IPO price band of ₹132. This indicates a substantial premium is being paid for the company's earnings and future growth potential, reflecting investor confidence in its business model and prospects.
Risks
- The company operates within the SME segment of the stock market, which is generally associated with higher volatility and liquidity risks compared to mainboard listed companies. Investors need to be prepared for potentially wider price swings and consider their risk appetite before investing in SME IPOs.
- A portion of the IPO, specifically ₹5.24 Cr, is an Offer for Sale (OFS), meaning these funds will go to selling shareholders and not towards the company's growth. While OFS provides liquidity to existing investors, it doesn't directly enhance the company's operational capacity or expansion plans.
- The exceptionally high RONW of 99.59%, while impressive, could also indicate a relatively small equity base or a period of unusually high profitability that might not be sustainable in the long term. Investors should analyze the sustainability of such high returns.
- Detailed historical financial data beyond the immediate reporting period is not readily available for this IPO, making it challenging to assess long-term revenue trajectory and consistent profitability trends. A deeper dive into historical performance would provide a more comprehensive understanding of the company's financial health.
- The company's Net Asset Value (NAV) of ₹16.05 per share is considerably lower than the IPO price band of ₹132. This implies a significant premium over book value, which, while justified by earnings, could be a point of concern if future growth doesn't meet market expectations.
Bio Medica Laboratories IPO Details
| Company Name | Bio Medica Laboratories |
|---|---|
| IPO Type | SME |
| Exchange | NSE |
| Price Band | ₹132 - ₹139 |
| Face Value | ₹10 per share |
| Lot Size | 1000 shares |
| Min Investment | ₹139,000 |
| Total Issue Size | ₹52.43 Cr |
|---|---|
| Fresh Issue | ₹47.19 Cr |
| Offer for Sale | ₹5.24 Cr |
| Registrar | Skyline Financial Services Pvt.Ltd. |
| Lead Manager | List of Issues managed, Narnolia Financial Services Ltd. |
| IPO Status | Listed |
Bio Medica Laboratories IPO Dates
Bio Medica Laboratories IPO Subscription Status
Day-wise Subscription Trend
| Date | Retail | NII/HNI | QIB | Total |
|---|---|---|---|---|
| 25 May 2026 | 2.92x | 1.41x | 15.94x | 2.31x |
| 22 May 2026 | 1.42x | 0.38x | 15.94x | 1.06x |
| 21 May 2026 | 1.09x | 0.03x | 15.94x | 0.72x |
Bio Medica Laboratories IPO Listing Performance
Bio Medica Laboratories IPO listed on NSE on 29 May 2026 at ₹111, a discount of 20% below the issue price of ₹139. Investors who received allotment faced a loss of ₹27,800 per lot (1000 shares) on listing day.
Bio Medica Laboratories IPO — Key Highlights
- Bio Medica Laboratories reported a substantial Profit After Tax (PAT) of ₹8.66 Cr on revenues of ₹28.55 Cr, indicating strong profitability.
- The company exhibits an exceptionally high Return on Net Worth (RONW) of 99.59%, showcasing its efficiency in generating profits from shareholder equity.
- With an EBITDA Margin of 39.83%, Bio Medica Laboratories demonstrates robust operational profitability.
- The IPO's fresh issue component is substantial at ₹47.19 Cr, intended to fuel company growth and expansion.
- The P/E ratio of approximately 12.38x suggests a potentially attractive valuation relative to earnings.
- A strong ROCE of 48.2% highlights the company's effective use of its capital for generating profits.
Bio Medica Laboratories Financial Performance
| Metric (₹ Cr) | FY 2023* | FY 2024* | FY 2025* | 8M FY 2026 |
|---|---|---|---|---|
| Revenue | 16.23 | 15.25 | 38.20 | 28.55 |
| Expenses | 15.80 | 11.69 | 25.18 | 16.95 |
| Net Income (PAT) | 0.33 | 2.50 | 9.80 | 8.66 |
Bio Medica Laboratories IPO Valuations & Key Metrics
Valuation Ratios
| EPS | ₹10.67 |
|---|---|
| P/E Ratio | 12.38x |
| NAV | ₹16.05 |
| Debt/Equity | 1.020 |
Return Metrics
| RONW (%) | 99.59% |
|---|---|
| ROCE (%) | 48.20% |
| EBITDA Margin | 39.83% |
Bio Medica Laboratories IPO Reservation / Allocation
Bio Medica Laboratories IPO Lead Manager & Registrar
Book Running Lead Manager
List of Issues managed, Narnolia Financial Services Ltd.
IPO Registrar
Skyline Financial Services Pvt.Ltd.
Bio Medica Laboratories IPO — Frequently Asked Questions
What is Bio Medica Laboratories IPO GMP today?
As of today, the Grey Market Premium (GMP) for Bio Medica Laboratories IPO is not available at this time. GMP values are updated daily based on grey market activity.
What is the price band and lot size of Bio Medica Laboratories IPO?
Bio Medica Laboratories IPO has a price band of ₹132 to ₹139 per equity share with a face value of ₹10. The minimum lot size is 1000 shares, requiring a minimum investment of ₹139,000 at the upper band.
What are the important dates for Bio Medica Laboratories IPO?
Bio Medica Laboratories IPO opens for subscription on 21 May 2026 and closes on 25 May 2026. Allotment is expected on 26 May 2026. The shares are expected to list on NSE on 29 May 2026.
What is the investor category allocation in Bio Medica Laboratories IPO?
The shares are reserved as follows — Qualified Institutional Buyers (QIB): 1.00%, Non-Institutional Investors (NII/HNI): 48.98%, and Retail Individual Investors: 50.01%.
How can I apply for Bio Medica Laboratories IPO?
You can apply for Bio Medica Laboratories IPO through your bank's net banking ASBA facility or via UPI-based application through any stockbroker platform. Ensure you have sufficient funds in your bank account as the amount will be blocked until allotment. The registrar for this IPO is Skyline Financial Services Pvt.Ltd..
What is the subscription status of Bio Medica Laboratories IPO?
Bio Medica Laboratories IPO has been subscribed 2.31 times overall. Retail category: 2.92x, NII/HNI: 1.41x, QIB: 15.94x.
What is Bio Medica Laboratories IPO price band and lot size?
The Bio Medica Laboratories IPO is open with a price band of ₹132 to ₹132 per share. The lot size for this IPO is 1000 shares, meaning the minimum investment required is ₹132,000 (1000 shares x ₹132 per share). The face value of each share is ₹10.
Is Bio Medica Laboratories IPO worth investing in?
Bio Medica Laboratories presents a compelling case with strong financial metrics, including an impressive RONW of 99.59% and ROCE of 48.2%. Its P/E ratio of 12.38x appears reasonable given its profitability. However, it's crucial to consider the risks associated with the SME segment and the OFS component.
Investors should weigh the company's high margins and return ratios against potential volatility and the premium valuation over its Net Asset Value (NAV) of ₹16.05. Investors should consult a SEBI-registered financial advisor before making investment decisions.
What is Bio Medica Laboratories IPO GMP today?
Grey Market Premium (GMP) for the Bio Medica Laboratories IPO is an unofficial indicator of demand and potential listing gains. While specific GMP figures fluctuate and are not provided here, a positive GMP generally suggests strong investor interest and a potential premium on listing day. However, it's vital to remember that GMP is speculative and should not be the sole basis for investment decisions.
How to apply for Bio Medica Laboratories IPO?
You can apply for the Bio Medica Laboratories IPO through the ASBA (Application Supported by Blocked Amount) facility via your bank or through your stockbroker using the UPI (Unified Payments Interface) mechanism. Ensure you have a demat account to hold the shares. Funds will be blocked in your bank account until the shares are allotted, at which point they will be debited or released.